Mainstay Taps Ex-NuVasive President, COO To Succeed Crosby
Mainstay Medical, the developer of the ReActiv8 neurostimulation system for treating chronic low back pain, is bringing in new senior management talent from the spine device market as the company ramps up commercialization activities.
You may also be interested in...
Mainstay Medical is making steps towards the US commercialization of its neurostimulation system ReActiv8. The company announced a positive outcome from interim analysis of its US ReActiv8 B clinical trial which aims to gather data in support of an application for pre-market approval from the US FDA.
Jason Hannon, former president and COO of spinal device manufacturer NuVasive Inc., has officially assumed the role of CEO and director of Irish company Mainstay Medical. He replaces Peter Crosby, who announced he would step down from the business in September.
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.